DOPAVISION

Dopavision is pioneering the development of innovative solutions that target the eye's innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light. We are developing a game-changing intervention for childhood myopia that can be easily administered via a smartphone app. Our goal is to provide a clinically validated therapeutic to help in the fight against the global myopia crisis... Our lead product is MyopiaX®, a breakthrough technology targeting myopia in children and adolescents. It has the potential to become the first myopia intervention to target the eye's dopamine pathway using digitally delivered light. MyopiaX® leverages our patented, light-based technology to stimulate specific photosensitive cells in the retina with the aim of impacting myopia progression.

Also known as: Dopavision GmbH

Registration numbers: HRB 191088 (W)

Primary location: Berlin